All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The FDA user fee bill passed a Senate committee vote with a hefty 21-2 margin without a provision for drug reimportation, but the bill does include an amendment that would require that clinical trials both broaden access and enroll a body of patients that reflects the populations that would receive that therapeutic product.